Cambrex Karlskoga
Cambrex Karlskoga, a prominent subsidiary of Cambrex Corporation, is headquartered in Karlskoga, Sweden. Established in 1981, the company has become a key player in the pharmaceutical industry, specialising in the development and manufacturing of active pharmaceutical ingredients (APIs) and intermediates. With a strong focus on quality and compliance, Cambrex Karlskoga has achieved significant milestones, including certifications from regulatory bodies such as the FDA and EMA. The company offers a range of services, including custom synthesis and process development, which are distinguished by their commitment to innovation and efficiency. Cambrex Karlskoga's strategic location in Sweden allows it to serve a diverse clientele across Europe and North America, solidifying its position as a trusted partner in the pharmaceutical supply chain. With a reputation for excellence, Cambrex Karlskoga continues to contribute to advancements in drug development and manufacturing.
DitchCarbon Score
How does Cambrex Karlskoga's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Medical Device Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cambrex Karlskoga's score of 24 is higher than 72% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Cambrex Karlskoga's reported carbon emissions
In 2023, Cambrex Karlskoga reported total carbon emissions of approximately 2,849,000 kg CO2e for Scope 1 and 2, alongside 53,330,000 kg CO2e for Scope 3 emissions. This reflects a commitment to reducing greenhouse gas emissions significantly. The company has set ambitious reduction targets, aiming for a 52% decrease in Scope 1 and 2 emissions and a 42% reduction in Scope 3 emissions by 2030, using 2018 and 2020 as baseline years, respectively. These targets are part of a broader strategy to enhance sustainability within the pharmaceutical and biotechnology sectors. Cambrex's emissions data shows a downward trend in Scope 1 and 2 emissions, decreasing from 16,000,000 kg CO2e in 2017 to 2,849,000 kg CO2e in 2023. This indicates a strong commitment to improving operational efficiency and reducing environmental impact. The company is actively working towards these goals, contributing to global efforts to combat climate change.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|
| Scope 1 | - | - | - | - | - | 00,000,000 | - |
| Scope 2 | - | - | - | - | - | 0,000,000 | - |
| Scope 3 | - | - | - | 00,000,000 | 00,000,000 | 00,000,000 | 00,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Cambrex Karlskoga is committed to some reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
